SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its drug Tinlarebant, aimed at treating Stargardt disease (STGD1). This designation is based on interim results from the Phase 3 DRAGON trial, showcasing Tinlarebant's efficacy and safety. Notably, there are currently no approved treatments for STGD1. This grant marks a significant step forward in addressing the serious unmet needs of the Stargardt community. Trial completion is expected by Q4 2025. Belite Bio has previously received multiple designations for Tinlarebant, including Fast Track and Rare Pediatric Disease Designations in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。